Protocols›Cognitive & neurological›Neuroprotection
← Protocols
Clinically used overseas · CerebrolysinIn human trials · SS-31Combination not approved

Neuroprotection

Stack: Cerebrolysin + Semax + SS-31 · neuroprotection / recovery
"Two of the three carry genuine clinical mileage — Cerebrolysin is a registered medicine in dozens of countries, Semax in Russia. SS-31 is still in trials. The three together as a single neuroprotection stack has never been studied in anyone."
GoalNeuroprotection / recovery
Compounds3 · Cerebrolysin + Semax + SS-31
Humans exposed (est.)High (Cerebrolysin, Semax)
StatusCerebrolysin: registered / clinically used in ~50 countries · Semax: RU-registered · SS-31 (elamipretide): in human trials, not approved · MHRA (UK)/FDA (US): combination not approved
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
Clinically used overseas
Where / who
Cerebrolysin is registered and used clinically in roughly 50 countries (Europe, Asia, Russia) for stroke, vascular dementia and TBI; Semax is a Russian-registered neuropeptide.
Use status
Decades of clinical use for both — large real-world exposure.
Evidence it adds
Real human exposure for two parts — trial results for Cerebrolysin are mixed/modest.
Basis: registration + clinical use abroad — strongest tier on this site
Combination not approved
Clinical record
No country lists this three-compound combination as an approved therapy.
Human trials
No trial has tested Cerebrolysin + Semax + SS-31 together. SS-31 (elamipretide) is itself still in trials and not approved anywhere.
Basis required for a clinical-use tag: none for the combination — absence shown, not hidden
Regulatory — read carefully
FDA (US)
None of the three is FDA-approved. SS-31 is in clinical development.
MHRA (UK)
Not licensed in the UK — all three sold as research material.
What it means
Overseas registration of Cerebrolysin/Semax is real public-use evidence, but is not MHRA/FDA approval.
Why it matters
UK pharmacovigilance does not cover them; SS-31 long-term human safety is still being established.
Basis: overseas registers (Cerebrolysin ~50 countries; Semax, Russia)
Why this combination

The logic is three different layers of neuroprotection: Cerebrolysin as a neurotrophic base (BDNF/GDNF-like activity, the strongest clinical record here), Semax for neuroprotective/cognitive support, and SS-31 targeting mitochondrial function. Each part has its own evidence; the combination has none, and SS-31 remains investigational. Strong free information, gated actionable depth.

Members only · the actionable depth
See exactly how it's run
Doses, cycle structure and what to monitor are part of membership. The provenance, evidence and exposure above are always free.
Get TiQ1 · Free →
Free · just create an account
Cycle shape — how it's typically structured, not a schedule to follow
Loading
build up
Maintenance
hold / taper
Off
stop / reassess
Convention from community use, not a prescription.
What's worth monitoring

With limited or no human safety data for this combination, there is no established marker set to monitor against — which is a reason for more caution, not less. Baseline bloods and a clinician conversation matter here. General information, not medical advice.

Combination evidence
Real-world uptake High

Cerebrolysin: ~50-country clinical use. Semax: Russian clinical use.

Human efficacy Mixed

Cerebrolysin RCTs modest/mixed; SS-31 trials ongoing; combination untested.

The honest ceiling

Two parts with real clinical mileage, one still in trials — but zero data on the three run together.

Fast facts
Compounds

Cerebrolysin · Semax · SS-31

Humans exposed (est.)

High (Cerebrolysin, Semax).

UK strip

GREEN — research material